Clinical Trials Logo
  1. Home
  2. Mature B-Cell Malignancies
  3. NCT04277637

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Mature B-Cell Malignancies Clinical Trial

Official title:
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04277637
Study type Interventional
Source BeiGene
Contact BeiGene
Phone 1-877-828-5568
Email clinicaltrials@beigene.com
Status Recruiting
Phase Phase 1
Start date March 24, 2020
Completion date August 30, 2027
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04883957 - Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies Phase 1
Active, not recruiting NCT04172246 - Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies Phase 1/Phase 2
Not yet recruiting NCT06351527 - Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies Phase 1